Bone and Mineral Metabolism Disorders News

WASHINGTON — In this Healio video exclusive, Javed Butler, MD, MPH, MBA, FACC, FAHA, FESC, discusses the results of the DIAMOND trial of patiromer for the reduction of hyperkalemia in patients with HF with reduced ejection fraction.

BOSTON — Trial results show patiromer is effective in controlling hyperkalemia and helps to reduce the risk of using blood pressure medications in patients with chronic kidney disease and heart failure.

WASHINGTON — Patiromer, a novel potassium binder, was associated with a reduction in hyperkalemia in patients with HF with reduced ejection fraction, enabling an increase in adherence to optimal medical therapy, researchers reported.

Among patients with nephrolithiasis, using smart water bottles to remind them to hydrate and record water intake can increase urine volume, according to data published in the Journal of Renal Nutrition.

Low-dose sevelamer in combination with a calcium-based phosphorus binder may be used in resource-constrained countries as a second-line therapy for patients with hyperphosphatemia to minimize calcium loading.

In addition to being male and of older age, being Black or Hispanic can increase a patient’s risk for hyperkalemia recurrence within 1 year of a hyperkalemia event, according to data presented at ASN Kidney Week.

A study of provider prescribing patterns revealed patients with advanced chronic kidney disease, especially those on dialysis, had lower rates of osteoporosis treatment than patients with earlier stages of kidney disease.

A meta-analysis of randomized controlled trials suggested magnesium supplementation alone might benefit patients on hemodialysis with chronic kidney disease-mineral bone disorder.

Older men with a skeletal mass index threshold below 42 cm2 per m2 experienced more hospitalizations with longer stays in the year following kidney transplantation than those who had a higher preoperative skeletal mass index.

While all the assessed instruments demonstrated a high prevalence of frailty in patients receiving hemodialysis, researchers from the United Kingdom found a 21.5% difference in frailty prevalence between the lowest and highest estimations.